AstraZeneca India announced on Monday the full results from the clinical trials of it’s latest diabetes drug, Dapagliflozin, showing significant benefits in reducing chronic kidney disease (CKD) progression in patients with and without type-2 diabetes. This CKD benefit is over and above the superior anti-diabetic and heart failure benefits.
In the early stages of chronic kidney disease, individualmay have few signs or symptoms, like swelling of the feet and ankles, itching, muscle cramps, nausea, vomiting and the lack of hunger.
However, chronic kidney disease may not become apparent until kidney function is significantly impaired. Getting evaluated with tests like Serum Creatinine, Blood Urea and Urine albumin are essential as a screening tool for individuals at risk.Once diagnosed, treatment for chronic kidney disease focuses on slowing the progression of the kidney damage, usually by controlling the underlying cause.
Chronic kidney disease can progress to end-stage kidney failure, which is fatal without dialysis or a kidney transplant.Kidney disease can lead to other health problems like heart failure, cardiovascular death, etc.
Detailed results from the ground-breaking Phase III DAPA-CKD trial showed that dapagliflozin along with standard of care reduced the worsening of renal function or risk of cardiovascular (CV) or renal death by 39% compared to placebo in patients with chronic kidney disease (CKD). The results were consistent in patients both with and without type-2 diabetes (T2D).